<table id="_RefID2DA5A371EA1D4F7EBD8B780594EB3F05" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>TABLE 4: Effect of Co-Administered Drugs on Total Ezetimibe </caption>
<col width="17%"></col>
<col width="10%"></col>
<col width="21%"></col>
<thead>
<tr stylecode="Toprule">
<th align="center" stylecode="Botrule Lrule " valign="top">
<content stylecode="bold">Co-Administered Drug and Dosing Regimen</content>
</th>
<th align="center" colspan="2" stylecode="Botrule Lrule " valign="top">
<content stylecode="bold">Total Ezetimibe </content>
<footnote id="_RefIDEF92C58F4C0C4182A5723ED51E8BF62E">Based on 10 mg dose of ezetimibe</footnote>
</th>
</tr>
<tr>
<th align="left" stylecode="Lrule Botrule " valign="top"></th>
<th align="center" stylecode="Lrule Botrule " valign="top">
<content stylecode="bold">Change in AUC</content>
</th>
<th align="center" stylecode="Lrule Botrule " valign="top">
<content stylecode="bold">Change in C<sub>max</sub>
</content>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<paragraph>Cyclosporine-stable dose required (75–150 mg BID)<footnote id="_RefIDD323896F60A74CEF964C97A19D348DD6">See <linkhtml href="#i4i_interactions_id_bd5b3f2e-9789-4fc0-a133-0d65d28787f5">Drug Interactions (7)</linkhtml>. </footnote>
<sup>,</sup>
<footnote id="_RefIDEB358F5E806641D7B6E1533E43C78C71">Post-renal transplant patients with mild impaired or normal renal function. In a different study, a renal transplant patient with severe renal insufficiency (creatinine clearance of 13.2 mL/min/1.73 m<sup>2</sup>) who was receiving multiple medications, including cyclosporine, demonstrated a 12-fold greater exposure to total ezetimibe compared to healthy subjects.</footnote>
</paragraph>
</td>
<td>
<paragraph>↑240%</paragraph>
</td>
<td>
<paragraph>↑290%</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Fenofibrate, 200 mg QD, 14 days<footnoteref idref="_RefIDD323896F60A74CEF964C97A19D348DD6"></footnoteref>
</paragraph>
</td>
<td>
<paragraph>↑48%</paragraph>
</td>
<td>
<paragraph>↑64%</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Gemfibrozil, 600 mg BID, 7 days<footnoteref idref="_RefIDD323896F60A74CEF964C97A19D348DD6"></footnoteref>
</paragraph>
</td>
<td>
<paragraph>↑64%</paragraph>
</td>
<td>
<paragraph>↑91%</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Cholestyramine, 4 g BID, 14 days<footnoteref idref="_RefIDD323896F60A74CEF964C97A19D348DD6"></footnoteref>
</paragraph>
</td>
<td>
<paragraph>↓55%</paragraph>
</td>
<td>
<paragraph>↓4%</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Aluminum &amp; magnesium hydroxide combination antacid, single dose<footnote id="_RefIDF56D166D4F5F4BA8B73F931C564F12F8">Supralox, 20 mL</footnote>
</paragraph>
</td>
<td>
<paragraph>↓4%</paragraph>
</td>
<td>
<paragraph>↓30%</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Cimetidine, 400 mg BID, 7 days</paragraph>
</td>
<td>
<paragraph>↑6%</paragraph>
</td>
<td>
<paragraph>↑22%</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Glipizide, 10 mg, single dose</paragraph>
</td>
<td>
<paragraph>↑4%</paragraph>
</td>
<td>
<paragraph>↓8% </paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>
<content stylecode="bold">Statins</content>
</paragraph>
</td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<paragraph>Lovastatin 20 mg QD, 7 days</paragraph>
</td>
<td>
<paragraph>↑9%</paragraph>
</td>
<td>
<paragraph>↑3%</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Pravastatin 20 mg QD, 14 days</paragraph>
</td>
<td>
<paragraph>↑7%</paragraph>
</td>
<td>
<paragraph>↑23%</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Atorvastatin 10 mg QD, 14 days</paragraph>
</td>
<td>
<paragraph>↓2%</paragraph>
</td>
<td>
<paragraph>↑12%</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Rosuvastatin 10 mg QD, 14 days</paragraph>
</td>
<td>
<paragraph>↑13%</paragraph>
</td>
<td>
<paragraph>↑18%</paragraph>
</td>
</tr>
<tr stylecode="Botrule">
<td>
<paragraph>Fluvastatin 20 mg QD, 14 days</paragraph>
</td>
<td>
<paragraph>↓19%</paragraph>
</td>
<td>
<paragraph>↑7%</paragraph>
</td>
</tr>
</tbody>
</table>